SubsidieMeestersRepair mechanisms of topoisomerase II DNA lesions
This project aims to elucidate the molecular mechanisms of TOP2-DNA-protein crosslink repair using Xenopus egg extracts, focusing on ZATT's role in coordinating repair pathways to enhance cancer treatment.
Projectdetails
Introduction
Topoisomerase II (TOP2) chemotherapeutics such as etoposide have been widely used in the clinic to treat leukemias, lymphomas, lung, testicular, and ovarian cancers. Etoposide was first approved for clinical usage in 1983. By intercalating into DNA, etoposide stalls the TOP2 catalytic cycle, generating toxic DNA lesions known as TOP2-DNA-protein crosslinks (TOP2-DPCs).
Research Background
After 40 years of intense research, the mechanisms employed by cells that counteract these lesions are starting to emerge. These include:
- Enzymes that reverse the crosslink
- Degradation of the protein adduct
- Removal of the lesion by DNA incisions
Moreover, the protein ZATT was recently described as an essential regulatory enzyme that SUMOylates TOP2 and thereby stimulates TOP2-DPC resolution.
Key Questions
Important and long-standing questions in the field relate to our understanding of how the different modes of repair are activated, coordinated between one another, and preferentially used by cells. Based on genetic data, ZATT appears to be the primary responder to TOP2-DPCs, but how ZATT coordinates the different modes of repair via TOP2-SUMOylation is currently unclear.
Proposed Approach
To address these questions and study TOP2-DPC repair, we propose to use a novel approach based on Xenopus egg extracts, which can recapitulate DNA repair mechanisms in a soluble environment.
Preliminary Data
As part of our preliminary data, we show that these extracts can recapitulate TOP2-DPC repair via ZATT SUMOylation, providing a unique opportunity to delineate the molecular mechanisms underlying this reaction.
Objectives
By combining this system with complementary and innovative approaches, we seek to obtain a clear molecular understanding of the different mechanisms counteracting TOP2 lesions and unravel the molecular triggers that activate the different routes of repair.
Impact
By doing this, we will provide new opportunities and targets to improve cancer treatment.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.000.000 |
| Totale projectbegroting | € 2.000.000 |
Tijdlijn
| Startdatum | 1-7-2024 |
| Einddatum | 30-6-2029 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- KOBENHAVNS UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Mechanism and targeting of topoisomerase regulatory interactions to arrest MYC-driven tumorsThis project aims to develop tumor-specific DNA topoisomerase inhibitors by targeting MYC-driven regulatory mechanisms, reducing toxicity while effectively halting tumor growth. | ERC Consolid... | € 1.996.750 | 2024 | Details |
Mechanisms at the interface of DNA damage repair and transcriptionThis project aims to elucidate the mechanisms of transcription-coupled repair and resolution of transcription-replication conflicts at DNA lesions using innovative genomic and proteomic approaches. | ERC Consolid... | € 1.999.764 | 2022 | Details |
Overcoming Resistance to Anti-cancer Drugs by Blocking Mutation-prone DNA Polymerases and the SOS ResponseThe ResistSOS project aims to eradicate lung cancer resistance to EGFR TKIs by combining mutagenic inhibitors with agents that disarm mutators, potentially curing the disease through a targeted approach. | ERC Advanced... | € 2.500.000 | 2023 | Details |
From understanding to rational design of next-generation cancer therapiesThe project aims to enhance cancer treatment efficacy by combining immunotherapy with ultra-low dose therapies to exploit sublethal damage in tumor cells, improving tolerability and clinical outcomes. | ERC Advanced... | € 2.499.893 | 2022 | Details |
Intercellular trading in nucleotide metabolism: an emerging targetThis project aims to identify nucleotide sources and metabolic interactions in cancer and stromal cells using single-cell multi-omics to develop targeted therapies against nucleotide-dependent tumors. | ERC Starting... | € 1.450.000 | 2022 | Details |
Mechanism and targeting of topoisomerase regulatory interactions to arrest MYC-driven tumors
This project aims to develop tumor-specific DNA topoisomerase inhibitors by targeting MYC-driven regulatory mechanisms, reducing toxicity while effectively halting tumor growth.
Mechanisms at the interface of DNA damage repair and transcription
This project aims to elucidate the mechanisms of transcription-coupled repair and resolution of transcription-replication conflicts at DNA lesions using innovative genomic and proteomic approaches.
Overcoming Resistance to Anti-cancer Drugs by Blocking Mutation-prone DNA Polymerases and the SOS Response
The ResistSOS project aims to eradicate lung cancer resistance to EGFR TKIs by combining mutagenic inhibitors with agents that disarm mutators, potentially curing the disease through a targeted approach.
From understanding to rational design of next-generation cancer therapies
The project aims to enhance cancer treatment efficacy by combining immunotherapy with ultra-low dose therapies to exploit sublethal damage in tumor cells, improving tolerability and clinical outcomes.
Intercellular trading in nucleotide metabolism: an emerging target
This project aims to identify nucleotide sources and metabolic interactions in cancer and stromal cells using single-cell multi-omics to develop targeted therapies against nucleotide-dependent tumors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.